Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

LXRX

+ Watchlist+ Portfolio

Lexicon Pharmaceuticals, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.78
52-Week Range
$1.10 – $2.68
Market Cap
$765.80M
P/E (TTM)
—
EPS (TTM)
-0.15
Dividend Yield
0.00%
Advanced Metrics
Price/Book
4.67
PEG Ratio
-13.77
Return on Equity
-43.91%
Return on Assets
-15.85%
Gross Margin
91.40%
Operating Margin
-147.42%
Profit Margin
-161.80%
Current Ratio
10.63
Debt/Equity
0.36
Total Debt
$59.54M
Free Cash Flow
$-27.89M
Revenue Growth
-20.70%
Earnings Growth
—
Enterprise Value
$642.14M

Market Snapshot

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing precision medicines for serious chronic conditions. The company markets Xermelo for carcinoid syndrome diarrhea and has a pipeline addressing cardiovascular, metabolism, and other therapeutic areas. Lexicon utilizes its proprietary gene knockout technology platform to identify and validate novel drug targets.